Helsinn announces publication of new data evaluating impact of NEPA (netupitant/palonosetron) on hospital costs Helsinn announces publication of new data evaluating impact of NEPA (netupitant/palonosetron) on hospital costs Lugano, Switzerland, February 3, 2023 - Helsinn Group (“Helsinn”), a fully integrated...

Helsinn announces presentation on CINV trial at European Society for Medical Oncology (ESMO) Asia Helsinn announces presentation on CINV trial at European Society for Medical Oncology (ESMO) Asia Lugano, Switzerland, November 29, 2022 - Helsinn Group (“Helsinn”), a fully integrated global...

Verity Pharmaceuticals™ and Helsinn Therapeutics sign exclusive agreement for the promotion of Akynzeo® and Valchlor® in Puerto Rico Verity Pharmaceuticals™ and Helsinn Therapeutics sign exclusive agreement for the promotion of Akynzeo® and Valchlor® in Puerto Rico Toronto, Ontario and Lugano, Switzerland, February 16, 2022 ...

Helsinn announces European Commission approval of the liquid formulation of AKYNZEO® (fosnetupitant/palonosetron) Helsinn announces European Commission approval of the liquid formulation of AKYNZEO® (fosnetupitant/palonosetron) Lugano, Switzerland, December 2, 2021 – Helsinn Group, a fully integrated, global...

Helsinn to present two posters at the San Antonio Breast Cancer Symposium (SABCS) 2020 evaluating high CINV recurrence in breast cancer patients and CINV duration as its predictor Helsinn to present two posters at the San Antonio Breast Cancer Symposium (SABCS) 2020 evaluating high CINV recurrence in breast cancer patients and CINV duration as its predictor   Lugano,...